SEARCH

SEARCH BY CITATION

References

  • 1
    Wiersma S. The global burden of disease of viral hepatitis. Viral Hepat 2011; 19: 910.
  • 2
    Kleinman SH, Lelie N, Busch MP. Infectivity of human immunodeficiency virus-1, hepatitis C virus and hepatitis B virus and risk of transmission by transfusion. Transfusion 2009; 49: 24542489.
  • 3
    WHO. Hepatitis B fact sheet no. 204, 2009. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/. (Accessed on 12 July 2011).
  • 4
    European Liver Patients Association (ELPA). Report on hepatitis patient self-help in Europe. Available at: http://www.hepsummit2010.org (Accessed on 11 July 2011).
  • 5
    Institute of Medicine. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: The National Academies Press, 2010.
  • 6
    European Centre for Disease Prevention and Control (ECDC). Surveillance and prevention of hepatitis B and C in Europe. ECDC technical report, Stockholm, October 2010.
  • 7
    European Centre for Disease Prevention and Control (ECDC). Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies. ECDC technical report, Stockholm, September 2010.
  • 8
    Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48(2): 335352.
  • 9
    Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127(5 Suppl. 1): S35S50.
  • 10
    Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Risk evaluation of viral load elevation and associated liver disease/cancer-In HBV (the REVEAL-HBV) study group. Gastroenterology 2006; 130(3): 678686.
  • 11
    Chen C-J, Yang H, Su J et al. , for the REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295(1): 6573.
  • 12
    Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: 535546.
  • 13
    Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology 2008; 134(6): 16991714.
  • 14
    McDonald SA, Hutchinson SJ, Bird SM et al. Excess morbidity in the hepatitis C-diagnosed population in Scotland, 1991–2006. Epidemiol Infect 2011; 139: 344353.
  • 15
    Ribes J, Clèries R, Esteban L, Moreno V, Bosch FX. The influence of alcohol consumption and hepatitis B and C infections on the risk of liver cancer in Europe. J Hepatol 2008; 49(2): 233242.
  • 16
    Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma, 1980–2004. Hepatology 2008; 48(1): 137145.
  • 17
    Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 19071917.
  • 18
    Degos F, Christidis C, Ganne-Carrie N et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000; 47(1): 131136.
  • 19
    Sangiovanni A, Prati GM, Fasani P et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 217 patients. Hepatology 2006; 43(6): 13031310.
  • 20
    Chang M-H, You S-L, Chen C-J et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccines: a 20-year follow-up study. J Natl Cancer Inst 2009; 101: 13481355.
  • 21
    Zanetti A, van Damme P, Shouval D. The global impact of vaccination against hepatitis B. A historical overview. Vaccine 2008; 26: 62666273.
  • 22
    Hernàn MA, Jick SS, Olek MJ, Jick H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis. A prospective study. Neurology 2004; 63: 838842.
  • 23
    Mikaeloff Y, Caridade G, Suissa S et al. Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood. Neurology 2009; 72: 873880.
  • 24
    World Health Organization global advisory committee on vaccine safety: Response to the paper by MA Hernan and others in Neurology 14th September 2004 issue entitled “Recombinant hepatitis B vaccine and the risk of multiple sclerosis”. Available at: http://www.who.int/vaccine_safety/topics/hepatitisb/multiple_sclerosis/sep_04/en/ (Accessed 11 July 2011).
  • 25
    Zanetti AR, Mariano A, Romanò L et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005; 366: 13791384.
  • 26
    West DJ, Calandra GB. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 1996; 14: 10191027.
  • 27
    Banatvala JE, Van Damme P. Hepatitis B vaccine: do we need boosters? J Hepatol 2003; 10: 16.
  • 28
    European Consensus on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 2000; 355: 561565.
  • 29
    Kao J-H, Chen DS. Hepatitis B vaccination: to boost or not to boost? Lancet 2005; 366: 13371338.
  • 30
    Hutton DW, Tan D, So SK, Brandeau ML. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med 2007; 147: 460469.
  • 31
    Veldhuijzen IK, Toy M, Hahne SJ et al. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective. Gastroenterology 2010; 138(2): 522530.
  • 32
    Sroczynski G, Esteban E, Conrads-Frank A et al. Long term effectiveness of screening for hepatitis C virus infection. Eur J Pub Health 2009; 19: 245253.
  • 33
    Viral hepatitis prevention Board. Identification and management of persons with chronic viral hepatitis in Europe, Budapest, March 2010. Viral Hepat 2011; 1(19): 140. Available at: http://www.vhpb.org.
  • 34
    Janssen HLA, van Zonneveld M, Senturk H et al. , for the HBV 99-01 Study Group. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123129.
  • 35
    de Vries–Sluijs TEMS, Reijnders JGP, Hansen BE et al. Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology 2010; 139(6): 19341941.
  • 36
    Chang T-T, Lai C-L, Yoon SK et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B. Hepatology 2010; 51(2): 422430.
  • 37
    Veldt BJ, Heathcote EJ, Wedemeyer H et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677684.
  • 38
    Buti M, Brosa M, Casado MA, Rueda MA, Esteban R. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol 2009; 51: 640646.
  • 39
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 24564.
  • 40
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50(2): 227242.
  • 41
    Rausch A, Kutalik Z, Descombes P et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure – a genome-wide association study. Gastroenterology 2010; 138: 133845;e7.
  • 42
    Mallet V, Gilgenkrantz H, Serpaggi J et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008; 149: 399403.
  • 43
    Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30(1): 6174.
  • 44
    Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. AADSL update. Hepatology 2011; 53: 10201022.
  • 45
    Bruix J, Sherman M, Llovet JM et al. EASL panel of experts on HCC. J Hepatol 2001; 35(3): 421430.
  • 46
    Carballo M, Cody R, O’Reilly E. International centre for migration, health and development. Migration, hepatitis B and C, September 2010. Available at: http://www.hepsummit2010.org.
  • 47
    Marschall T, Krämer A, Prüfer-Krämer L, Mikolajczyk R, Kretzschmar M. Does migration from high and intermediate endemic regions increase the prevalence of hepatitis B infection in Germany? Dtsch Med Wochenschr 2005; 130(48): 27532758. [Article in German].
  • 48
    Rechel B, Blackburn CM, Spencer NJ, Rechel B. Access to health care for Roma children in Central and Eastern Europe: findings from a qualitative study in Bulgaria. Int J Equity Health 2009; 8: 24.
  • 49
    Carballo M. The process of social insertion of migrants, refugees and asylum seekers in the context of access to and use of health and social services. Synthesis and recommendations. ICMH/Synthese Geneva report 2004.
  • 50
    Wiessing L, Guarita B, Giraudon H, Brummer-Korvenkontio H, Salminen M, Cowan SA. European monitoring of notifications of hepatitis C virus infection in the general population and among injecting drug users (IDUs) – the need to improve quality and comparability. Eurosurveillance 2008; 13(21): 15.
  • 51
    Hagan H, Snyder N, Hough E et al. Case-reporting of acute hepatitis B and C among injection drug users. J Urban Health 2002; 79: 579585.
  • 52
    Wiessing L, Blystad H. EMCDDA publishes guidelines on testing for HIV, viral hepatitis and other infections in injecting drug users. Euro Surveill 2010;15(48): pii=19735. Available at: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19735 (Accessed 11 July 2011)
  • 53
    Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 2011; 54(6): 113744.
  • 54
    Montaner JS, Lima VD, Barrios R et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010; 376(9740): 532539.
  • 55
    Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injecting drug users: a review of available evidence. Clin Infect Dis 2009; 49(4): 561573..
  • 56
    Dalgard O. Follow up studies of treatment for hepatitis C virus infection among injecting drug users. Clin Infect Dis 2005; 40(s5): S336S338.
  • 57
    EMA. Guideline: clinical evaluation of medicinal products intended for treatment of hepatitis B, 2006. adopted February 2006.
  • 58
    EMA. Guideline: clinical evaluation of direct acting antiviral agents intended for treatment of chronic hepatitis C, 2009. adopted May 2009.
  • 59
    Delarocque-Astagneau E, Meffre C, Dubois F et al. , Hepatitis C Surveillance System Committee; Scientific Committee for the National Prevalence Survey of Hepatitis B and C Markers. Hepatitis C Surveillance System Committee; Scientific Committee for the National Prevalence Survey of Hepatitis B and C Markers. The impact of the prevention programme of hepatitis C over more than a decade: the French experience. J Viral Hepat 2010; 17(6): 435443.
  • 60
    Lettmeir B, Mühlberger N, Schwarzer R et al. Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol 2008; 49: 528535.